cmAngio® vs Rapid RV/LV
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your institution aims to proactively assess cardiovascular risk in women by leveraging existing mammography screenings. This tool is ideal for identifying Breast Arterial Calcifications (BAC) to provide early insights into potential cardiovascular health concerns without requiring additional radiation or procedures, seamlessly integrating into routine radiology workflows.
View cmAngio® →Choose Rapid RV/LV if…
Choose Rapid RV/LV if your priority is the rapid and objective assessment of pulmonary embolism (PE) severity in acute or emergency care settings. This AI tool is specifically designed to quickly measure right and left ventricle ratios from CTPA scans, providing critical information within minutes to aid in timely clinical decision-making and patient triage for suspected PE cases.
View Rapid RV/LV →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | Rapid RV/LV |
|---|---|---|
| Pricing | Paid, out-of-pocket | Contact vendor for pricing information. |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Unknown |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngiou00ae (Tool A) emphasizes quick and easy installation (less than an hour) and broad compatibility with any DICOM-compliant viewer, suggesting a smoother integration into existing clinical workflows. Its cloud-based deployment also generally simplifies IT overhead compared to on-premises solutions.
Clinical Value
cmAngio®Both tools are FDA-cleared and offer significant clinical value. However, cmAngiou00ae (Tool A) demonstrates a unique value proposition by leveraging existing mammography data to provide novel insights into cardiovascular health through Breast Arterial Calcification (BAC) detection, without requiring additional radiation or procedures. This opportunistic screening approach adds a new layer of proactive risk assessment from routine exams.
Pricing & Value
TieBoth cmAngiou00ae (Tool A) and Rapid RV/LV (Tool B) require direct contact with the vendor for pricing information, making it impossible to conduct a head-to-head comparison on cost or overall value proposition. Neither provides publicly available pricing details or specific ROI studies.
Enterprise Readiness
Rapid RV/LVWhile both are HIPAA-compliant and FDA-cleared, Rapid RV/LV (Tool B) explicitly confirms having a Business Associate Agreement (BAA) and offers flexible deployment options (on-premises or hybrid). This caters to a wider range of enterprise IT infrastructures and security policies, which can be crucial for larger healthcare organizations.
Innovation
cmAngio®Both tools utilize AI for medical imaging analysis. However, cmAngiou00ae (Tool A) exhibits greater innovation by repurposing routine mammography scans to detect Breast Arterial Calcifications, thereby providing novel insights into cardiovascular health from an already performed exam. This 'secondary read' for a different clinical domain is a highly innovative application of AI.
Support & Docs
Rapid RV/LVRapid RV/LV (Tool B) clearly outlines its 24/7/365 global customer support via email and phone, and explicitly mentions a 'Help Center' and 'Documentation' as resources. In contrast, cmAngiou00ae (Tool A) provides contact details but lacks the same level of explicit detail regarding support availability or dedicated online resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | Rapid RV/LV |
|---|---|---|
| Tool Name | cmAngiou00ae | Rapid RV/LV |
| Company | CureMetrix | RapidAI (formerly iSchemaView) |
| Primary Clinical Focus | Detecting Breast Arterial Calcifications (BAC) on mammograms for cardiovascular health and early risk assessment. | Rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans. |
| Key AI Functionality | AI-based detection of Breast Arterial Calcifications (BAC); processes FFDM and DBT; provides visualization of BAC location on a scorecard. | AI-powered analysis of CTPA images; automated measurement of right and left ventricle diameters; calculation of RV/LV ratio; annotated images showing ventricular measurements. |
| Input Imaging Modality | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | CTPA scans |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and Rapid RV/LV.